<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="10.17917/95VC-ZP26" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><h2>NCL Method GTA-14: Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay</h2><hr><p>This protocol describes the monitoring of nanoparticle treated human hepatocarcinoma cells (HepG2) for apoptosis, as part of the in vitro NCL preclinical characterization cascade.  The protocol utilizes a fluorescent method to measure Caspase-3/7 activation.  This is a homogeneous assay that does not require cell isolation, as required for HepG2 Hepatocarcinoma Apoptosis Assay (NCL Method GTA-6).</p><h3>File name: protocols/20240410_18-45-43-167_NCL_Method_GTA-14.pdf</h3><h3>DOI: <a href = http://dx.doi.org/10.17917/95VC-ZP26>http://dx.doi.org/10.17917/95VC-ZP26</a></h3</body></html>